Celyad Presents Update on r/r AML and MDS Program at 61 st ASH Annual Meeting Future development of relapsed/refractory (r/r) acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) program to ...

Celyad (Euronext Brussels and Paris, and Nasdaq: CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T cell therapies, today announced updates to the company's ...

Through its Centers of Excellence program, the MDS Foundation helps patients get appointments with leading experts from around the world. For patients with cancer there is no time to waste. The MDS ...